Autres langues Acelyrin, Inc.

Actions

SLRN

US00445A1007

Temps réel estimé Cboe BZX Autres places de cotation 17:21:20 16/07/2024			Varia. 5j.	Varia. 1 janv.
6,71 ^USD	+9,46 %		+29,22 %	-11,66 %

05/06	Transcript : Acelyrin, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 01:00 PM
05/06	ACELYRIN, Inc. annonce que les résultats positifs à 16 semaines de son essai clinique mondial de phase 2b/3 sur l'izokibep dans le rhumatisme psoriasique seront communiqués lors d'une présentation orale de dernière minute à l'EULAR 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Acelyrin, Inc.(NasdaqGS:SLRN) added to Russell 3000E Index	01/07
Acelyrin, Inc.(NasdaqGS:SLRN) added to Russell Microcap Index	01/07
Acelyrin, Inc.(NasdaqGS:SLRN) dropped from Russell 2500 Growth Index	01/07
Acelyrin, Inc.(NasdaqGS:SLRN) dropped from Russell Small Cap Comp Growth Index	01/07
Acelyrin, Inc.(NasdaqGS:SLRN) dropped from Russell 3000E Growth Index	01/07
Acelyrin, Inc.(NasdaqGS:SLRN) dropped from Russell 3000 Growth Index	01/07
Acelyrin, Inc.(NasdaqGS:SLRN) dropped from Russell 2000 Growth Index	01/07
Acelyrin, Inc.(NasdaqGS:SLRN) added to Russell Microcap Value Index	01/07
Acelyrin, Inc.(NasdaqGS:SLRN) added to Russell 3000E Value Index	01/07
Acelyrin : Corporate Presentation (5c90da81 2070 4a9b 893f 4f5b1d625ce8)	15/06
Efficacy and Safety of Izokibep, a Novel IL 17A Inhibitor, in Patients with Active Psoriatic Arthritis: Week 16 Results from a Randomized, Double Blind, Placebo Controlled, Multicenter Phase 2b/3 Study	15/06
ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024	05/06
ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024	05/06
ACELYRIN, Inc. Announces Positive 16-Week Data from its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to Be Shared During Late-Breaking Oral Presentation at EULAR 2024	05/06
Acelyrin : Preliminary Safety And Efficacy Of Subcutaneous Lonigutamab (anti IGF 1R) From A Phase 1/2 Proof Of Concept Study In Patients With Thyroid Eye Disease	03/06
ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024	29/05
Acelyrin, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
Acelyrin, Inc. Announces Ron Oyston to Step Down as Chief People Officer, Effective August 15, 2024	09/05
ACELYRIN, INC. Announces Leadership Transition	09/05
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones	09/05

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Acelyrin, Inc.

Actions

SLRN

US00445A1007

Autres langues

Filtres